CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Kim A. Reiss(University of Pennsylvania), Yara Abdou(University of North Carolina at Chapel Hill), Maggie Schmierer(Carisma Therapeutics (United States)), Joseph Chao(Amgen (United States)), Michael Klichinsky(Carisma Therapeutics (United States)), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Mathew G. Angelos(University of Pennsylvania), Jonathan S. Serody(University of North Carolina at Chapel Hill), Sabrina Ceeraz DeLong(Carisma Therapeutics (United States)), Débora Barton(Carisma Therapeutics (United States)), Ramona F. Swaby(Merck & Co., Inc., Rahway, NJ, USA (United States)), Saar Gill(Parker Institute for Cancer Immunotherapy), Melissa L. Johnson(Tennessee Oncology), Melissa Christiano(Carisma Therapeutics (United States)), E. Claire Dees(University of North Carolina at Chapel Hill), Olga Shestova(University of Pennsylvania), Ken Locke(Carisma Therapeutics (United States)), Poonam Sonawane(Carisma Therapeutics (United States)), Sascha Abramson(Carisma Therapeutics (United States)), Michael Ball(Carisma Therapeutics (United States)), Eugene P. Kennedy(Chevron (Australia)), Thomas Condamine(Carisma Therapeutics (United States)), Madison Kremp(Carisma Therapeutics (United States)), Benjamin H. Schott(Carisma Therapeutics (United States)), Naoto T. Ueno(Breast Cancer Care), Yuan Yuan(Cedars-Sinai Medical Center), Daniel J. Cushing(Carisma Therapeutics (United States)), Rehman Qureshi(Carisma Therapeutics (United States))
Cited by 189
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835